We use cookies to improve your experience and for marketing. Read our cookie policy or manage cookies.

Accept essential cookies
Accept all cookies
Sign in
Sign in
Companies → CHINA SHINEWAY PHARMACEUTICAL GROUP LIMITED
Save to list
Remove

CHINA SHINEWAY PHARMACEUTICAL GROUP LIMITED

Hong Kong SAR, Wan Chai
Report a bug?
Claim ownership and edit
Description
by AI
China Shineway Pharmaceutical Group Limited engages in the development, manufacture, and sale of active pharmaceutical ingredients, pharmaceutical intermediates, and related products in the People's Republic of China, United States, Europe, and Asia. It offers antibiotics, such as semi-synthetic penicillin, penicillin G procaine, acylureidopenicillins, cephalosporins, and carbapenems; anti-tumor drugs, including camptothecins and taxanes; as well as cardiovascular and cerebrovascular drugs comprising ACE inhibitors, statins, anti-platelet drugs, and calcium antagonists. The company also provides amino acids, such as glycine and L-isoleucine; and chiral intermediates. In addition, it offers custom development and manufacturing services, as well as analytical testing, registration support, and quality control services. The company was founded in 1998 and is headquartered in Wan Chai, Hong Kong. China Shineway Pharmaceutical Group Limited is a subsidiary of Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Industries
SIC
Address:

Rm 3109 31/F CENTRAL PLZ 18 HARBOUR RD Wan Chai Hong Kong

Website:
Revenue
Recent news:

Asian Dividend Stocks To Consider For Your Portfolio

As Asian markets navigate a landscape marked by Japan's highest interest rates in three decades and mixed economic indicators from China, investors are increasingly looking toward dividend stocks as a potential source of stable income. In such an environment, selecting stocks with strong fundamentals and consistent dividend payouts can be crucial for building a resilient portfolio.

Source: Simply Wall St. Dec 24, 2025

OTC - Delayed Quote - USD
CSWYY
19.25 0.00 (0.00%)
At close March 20 20:00 UTC
Candle
Line
1D
5D
1M
6M
1Y
5Y
Financial Statistics
Valuation Measures
Current
Quarterly
As of 03/20/2026
Market Cap: 856.02 M
Enterprise Value: -107.08 M
Trailing P/E: 6.23
Forward P/E: N/A
PEG Ratio (5yr expected): N/A
Price/Sales (ttm): 0.23
Price/Book (mrq): 12.85
Enterprise Value/Revenue: 2.37
Enterprise Value/EBITDA: 11.40
Financial Highlights
Profitability and Income Statement
Profit Margin: 24.77%
Return on Assets (ttm): 3.99%
Return on Equity (ttm): 10.94%
Revenue (ttm): 3.34 B
Net Income Avi to Common (ttm): 828.24 M
Diluted EPS (ttm): 3.09
Balance Sheet and Cash Flow
Total Cash (mrq): 6.96 B
Total Debt/Equity (mrq): 4.37%
Levered Free Cash Flow (ttm): 555.68 M
Company is likely to buy
Company is likely to sell
Disclaimer:

IndexBox is not affiliated with, associated with, or endorsed by this company in any way. The information provided on this page, including company details, is solely for informational purposes. IndexBox makes no representations or warranties about the accuracy or completeness of the information provided.

All data and information is provided “as is” for informational purposes only, and is not intended for trading purposes or financial, investment, tax, legal, accounting or other advice. Please consult your broker or financial representative to verify pricing before executing any trade. IndexBox is not an investment adviser, financial adviser or a securities broker. None of the data and information constitutes investment advice nor an offering, recommendation or solicitation by IndexBox to buy, sell or hold any security or financial product, and IndexBox makes no representation (and has no opinion) regarding the advisability or suitability of any investment.